無菌製藥加工設備市場－全球產業規模、佔有率、趨勢、機會及預測（按組件、應用、地區及競爭格局分類），2021-2031年

全球無菌製藥加工設備市場預計將從2025年的97.7億美元成長到2031年的136.5億美元，複合年成長率（CAGR）為5.73%。該行業專注於專用機械和隔離系統，旨在對藥品和包裝材料進行單獨滅菌，然後在無菌區域組裝。該行業的成長主要受全球對注射劑（尤其是疫苗和生物製藥）需求不斷成長以及藥品生產品質管理規範（GMP）法規的嚴格執行所驅動，後者要求更高的無菌保證。此外，透過自動化解決方案減少人為干預的需求也是推動該產業發展的重要因素。根據包裝與加工技術協會（APPT）2024年的報告，83%的製藥企業在選擇新設備時優先考慮設備的可靠性和可重複性，這凸顯了滿足這些嚴格標準的高性能系統的緊迫性。

儘管成長前景良好，但先進無菌技術所需的大量資本投資構成了市場面臨的重大障礙。實施和檢驗複雜的隔離系統（例如隔離器和限制存取屏障系統）需要大量的前期投資和專業技術知識，這可能會阻礙預算有限的小型製造商對其基礎設施進行現代化改造。因此，這些財務和營運方面的障礙可能會阻礙下一代加工解決方案的廣泛應用，並減緩新興地區整體市場的發展。

市場促進因素

對無菌注射劑和腸外製劑的需求不斷成長，正在從根本上改變整個產業，迫使製造商迅速擴大其無菌加工能力。這種趨勢在爭奪高需求生物製藥（例如GLP-1受體促效劑，這些藥物需要部署高速、無污染的填充生產線。大型製藥公司正積極收購契約製造資源，以確保這些敏感產品的供應鏈穩定性和無菌性。例如，諾和諾德（Novo Holdings）於2024年2月宣布，已同意以165億美元的現金交易收購Catalent，此舉旨在加強其糖尿病和減重治療產品組合的無菌生產能力。

同時，為消除無菌環境中的人為錯誤，先進機器人技術和工業4.0自動化技術的應用成為推動設備普及的關鍵因素。現代化的無菌設施正朝著全自動物料輸送系統和無手套機器人隔離器的方向發展，這些系統和隔離器在最佳化生產效率的同時，也能確保符合嚴格的監管標準。這一轉變得益於全行業的數位轉型，旨在提高營運效率和批次一致性。根據羅克韋爾自動化公司2024年3月發布的《智慧製造現況：生命科學》報告，96%的生命科學製造商目前正在利用或評估智慧製造技術。這波技術升級浪潮與大規模資本計劃相輔相成，例如禮來公司宣布將於2024年追加投資53億美元，用於擴建其位於印第安納州的製造地，凸顯了新建設施對先進無菌設備的巨大需求。

市場挑戰

全球無菌製藥加工設備市場面臨巨大的限制，這主要是由於實施和驗證先進的防護技術需要大量的資本支出。諸如限制性存取屏障系統和隔離器等系統的實施需要大量的前期投資，不僅包括購買設備，還包括昂貴的設施維修和專用公用設施的安裝。此外，嚴格的驗證階段進一步加重了這項財務負擔，製造商必須在此階段投入額外成本，以證明其符合嚴格的無菌標準，生產才能開始。

這些經濟壓力造成了很高的進入門檻，阻礙了自動化加工解決方案的廣泛應用，尤其是在新興經濟體企業和中小型契約製造組織（CMO）中。高昂的總擁有成本有效地阻止了預算緊張的營業單位升級其設施，從而減緩了整個行業透過自動化實現無菌保證的進程。根據國際製藥工程協會（ISPE）的數據，在2024年接受調查的業內人士中，近50%的人認為監管複雜性和經濟因素是採用創新製造技術的主要障礙。這凸顯了資金限制如何透過阻礙必要的現代化投資而直接限制市場成長。

市場趨勢

向模組化、靈活的生產設施轉型正在改變投資策略。為了管理多元化的產品線，製藥公司越來越重視敏捷性，而非專用的單一生產線。與傳統的、固定的、不銹鋼生產線（專為大批量、單劑量生產而建）不同，現代化的生產設施配備了可靈活調整的加工模組，能夠快速切換產品並同時生產多種生物製藥。這種運作柔軟性對於希望平衡重磅藥物和小批量治療藥物生產的製造商至關重要，因為它無需為每種藥物單獨建造工廠。賽諾菲在2024年5月投資超過10億歐元在法國建立新的生物製劑生產能力，就是這項策略轉變的顯著例證。該公司專門設計了位於維特里-塞納河畔的工廠，使其能夠靈活生產多種適應症的治療藥物，包括多發性硬化症、氣喘和慢性阻塞性肺病（COPD）。

同時，自體細胞和基因療法的商業化，由於需要高度密閉和低產量生產環境，正在加速個人化醫療小規模批量加工設備的研發。由於患者特異性療法無法在高速填充線上進行加工，市場需要專用的封閉式系統設備來處理小批量生產，並徹底消除交叉污染的風險。這一趨勢迫使設備開發商放棄以速度為導向的設計，轉而開發優先考慮高價值生物製藥的密閉性和精確性的系統。Astra Zeneca在2024年2月宣布將在馬裡蘭州羅克維爾投資3億美元，建立一個專注於推出其細胞療法平台並生產用於商業供應和臨床試驗的T細胞療法的專門設施，這一舉措凸顯了對該領域的關注。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球無菌製藥加工設備市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依組件分類（加工設備（乾燥設備、擠出機、研磨機、製粒設備、壓片機、送料機、填充和精加工設備、混合設備、氣動輸送設備）、包裝設備（檢測機、貼標機、無菌包裝機））
  • 依應用方式（眼用混懸液、無菌注射液、注射用凍乾粉、吸入用水性氣霧劑等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美無菌製藥加工設備市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲無菌製藥加工設備市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區無菌製藥加工設備市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲無菌製藥加工設備市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲無菌製藥加工設備市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球無菌製藥加工設備市場：SWOT分析

第14章 波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Robert Bosch GmbH
• DuPont plc.
• SPX Flow, Inc.
• Industria Macchine Automatiche SPA
• Becton, Dickinson, and Company
• AMCOR plc
• GEA Group
• Greatview Aseptic Packaging Co., Ltd.
• John Bean Technologies（JBT）Corporation
• Automated Systems of Tacoma, LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Aseptic Pharma Processing Equipment Market is projected to expand from USD 9.77 Billion in 2025 to USD 13.65 Billion by 2031, reflecting a compound annual growth rate of 5.73%. This industry segment focuses on specialized machinery and containment apparatuses engineered to independently sterilize pharmaceutical products and packaging prior to assembly within a contamination-free zone. Growth in this sector is largely fueled by rising global requirements for parenteral therapeutics, specifically vaccines and biologics, alongside stringent regulatory enforcement of Good Manufacturing Practices that demand superior sterility assurance. Additionally, the industry is motivated by the necessity to reduce human involvement via automated solutions. In 2024, the Association for Packaging and Processing Technologies reported that 83% of pharmaceutical manufacturers rank equipment reliability and repeatability as their primary concerns when selecting new machinery, highlighting the urgent need for high-performance systems that satisfy these exacting standards.

Despite this positive growth outlook, the market encounters significant hurdles related to the extensive capital expenditures needed for advanced aseptic technologies. Installing and validating intricate containment systems, including isolators and restricted access barrier systems, requires substantial upfront investment and specialized technical knowledge, which can discourage smaller manufacturers with tighter budgets from modernizing their infrastructure. As a result, these financial and operational obstacles may hinder the widespread adoption of next-generation processing solutions, potentially retarding overall market development in emerging regions.

Market Driver

The escalating demand for sterile injectables and parenteral therapeutics is fundamentally transforming the sector, forcing manufacturers to rapidly expand their aseptic processing capacities. This momentum is especially visible in the competitive rush to secure fill-finish capabilities for high-demand biologics, such as GLP-1 receptor agonists, which require the deployment of high-speed, contamination-free filling lines. Prominent pharmaceutical companies are actively acquiring contract manufacturing resources to ensure supply chain stability and sterility assurance for these delicate products. For instance, in a strategic effort to bolster sterile manufacturing capacity for its diabetes and weight-loss portfolios, Novo Holdings announced in February 2024 that it agreed to acquire Catalent in an all-cash transaction with an enterprise value of $16.5 billion.

At the same time, the incorporation of advanced robotics and Industry 4.0 automation serves as a vital driver for equipment adoption, spurred by the necessity to eradicate human error within sterile settings. Modern aseptic facilities are evolving toward fully automated material handling systems and gloveless robotic isolators that ensure adherence to rigorous regulatory standards while optimizing throughput. This transition is underpinned by widespread industry commitment to digital transformation aimed at improving operational efficiency and batch uniformity. According to Rockwell Automation's "State of Smart Manufacturing: Life Sciences Edition" report from March 2024, 96% of life sciences manufacturers are currently utilizing or assessing smart manufacturing technologies. This wave of technological upgrades aligns with massive capital projects, such as Eli Lilly's 2024 announcement of an additional $5.3 billion investment to expand its Indiana manufacturing site, underscoring the immense scale of new facilities demanding advanced aseptic machinery.

Market Challenge

The Global Aseptic Pharma Processing Equipment Market faces significant constraints due to the massive capital expenditures necessary to procure and validate advanced containment technologies. Deploying systems like restricted access barrier systems and isolators demands a heavy upfront investment that encompasses not only the purchase of machinery but also expensive facility retrofitting and specialized utility installations. This financial strain is further exacerbated during the rigorous validation phase, where manufacturers must bear extra costs to prove compliance with stringent sterility standards before production operations can begin.

These economic pressures establish a formidable barrier to entry that impedes the widespread adoption of automated processing solutions, especially among companies in emerging economies and smaller contract manufacturing organizations. The prohibitive total cost of ownership effectively prevents budget-constrained entities from updating their facilities, thereby slowing the industry-wide transition toward automated sterility assurance. According to the International Society for Pharmaceutical Engineering, nearly 50% of industry professionals surveyed in 2024 pinpointed regulatory complexities and economic factors as the main obstacles to adopting innovative manufacturing technologies. This evidence highlights how financial limitations directly restrict market growth by deterring investment in essential modernization.

Market Trends

The transition toward modular and flexible manufacturing facilities is altering investment strategies as pharmaceutical firms value agility over dedicated single-product lines to manage diverse pipelines. In contrast to traditional fixed stainless-steel lines built for high-volume mono-production, contemporary facilities are incorporating adaptable processing modules that facilitate rapid product changeovers and the concurrent manufacturing of various biologic modalities. This operational flexibility is crucial for manufacturers aiming to balance production between blockbuster drugs and lower-volume therapeutics without the need to build separate plants for each. A prime example of this strategic shift occurred in May 2024, when Sanofi committed over €1 billion to establish new bioproduction capacity in France, specifically designing its Vitry-sur-Seine site to flexibly manufacture treatments for diverse indications, including multiple sclerosis, asthma, and COPD.

Concurrently, the development of small-batch processing equipment for personalized medicine is gathering momentum, fueled by the commercialization of autologous cell and gene therapies that demand highly contained, low-volume manufacturing settings. Since these patient-specific treatments cannot be processed on high-speed filling lines, the market is seeing an increase in specialized, closed-system equipment engineered to manage micro-batches with zero risk of cross-contamination. This trend compels equipment developers to pivot from speed-focused designs to systems that emphasize containment integrity and precision for high-value biological materials. This sectoral focus was clearly demonstrated in February 2024, when AstraZeneca announced a $300 million investment in a specialized facility in Rockville, Maryland, explicitly dedicated to launching its cell therapy platforms and producing T-cell therapies for commercial supply and clinical trials.

Key Market Players

• Robert Bosch GmbH
• DuPont plc.
• SPX Flow, Inc.
• Industria Macchine Automatiche S.P.A.
• Becton, Dickinson, and Company
• AMCOR plc
• GEA Group
• Greatview Aseptic Packaging Co., Ltd.
• John Bean Technologies (JBT) Corporation
• Automated Systems of Tacoma, LLC

Report Scope

In this report, the Global Aseptic Pharma Processing Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Aseptic Pharma Processing Equipment Market, By Component

• Processing Equipment
  • Drying Equipment
  • Extruders
  • Mills
  • Granulation Equipment
  • Tablet Compression
  • Feeders
  • Fill/Finish Equipment
  • Mixing Equipment
  • Pneumatic Conveying Equipment
• Packaging Equipment
  • Inspection Machines
  • Labelling Machines
  • Aseptic Packaging Machines

Aseptic Pharma Processing Equipment Market, By Application

• Ophthalmic Suspensions
• Sterile Injectables
• Reconstituted Lyophilized Powders for Injection
• Aqueous-based Aerosols for Inhalation
• Others

Aseptic Pharma Processing Equipment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Aseptic Pharma Processing Equipment Market.

Available Customizations:

Global Aseptic Pharma Processing Equipment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Aseptic Pharma Processing Equipment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Processing Equipment (Drying Equipment, Extruders, Mills, Granulation Equipment, Tablet Compression, Feeders, Fill/Finish Equipment, Mixing Equipment, Pneumatic Conveying Equipment), Packaging Equipment (Inspection Machines, Labelling Machines, Aseptic Packaging Machines))
  • 5.2.2. By Application (Ophthalmic Suspensions, Sterile Injectables, Reconstituted Lyophilized Powders for Injection, Aqueous-based Aerosols for Inhalation, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Aseptic Pharma Processing Equipment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Aseptic Pharma Processing Equipment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Aseptic Pharma Processing Equipment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Aseptic Pharma Processing Equipment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Application

7. Europe Aseptic Pharma Processing Equipment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Aseptic Pharma Processing Equipment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Application
  • 7.3.2. France Aseptic Pharma Processing Equipment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Aseptic Pharma Processing Equipment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Aseptic Pharma Processing Equipment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Aseptic Pharma Processing Equipment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Application

8. Asia Pacific Aseptic Pharma Processing Equipment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Aseptic Pharma Processing Equipment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Application
  • 8.3.2. India Aseptic Pharma Processing Equipment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Aseptic Pharma Processing Equipment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Aseptic Pharma Processing Equipment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Aseptic Pharma Processing Equipment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Application

9. Middle East & Africa Aseptic Pharma Processing Equipment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Aseptic Pharma Processing Equipment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Aseptic Pharma Processing Equipment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Aseptic Pharma Processing Equipment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Application

10. South America Aseptic Pharma Processing Equipment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Aseptic Pharma Processing Equipment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Aseptic Pharma Processing Equipment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Aseptic Pharma Processing Equipment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Aseptic Pharma Processing Equipment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Robert Bosch GmbH
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. DuPont plc.
• 15.3. SPX Flow, Inc.
• 15.4. Industria Macchine Automatiche S.P.A.
• 15.5. Becton, Dickinson, and Company
• 15.6. AMCOR plc
• 15.7. GEA Group
• 15.8. Greatview Aseptic Packaging Co., Ltd.
• 15.9. John Bean Technologies (JBT) Corporation
• 15.10. Automated Systems of Tacoma, LLC

16. Strategic Recommendations

17. About Us & Disclaimer